Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

Laureate Pharma Inc. for cGMP manufacturing of humanized

antibody for Phase 1 clinical supply. A cell line producing the

humanized anti-Trop-2 antibody was successfully transferred to

Laureate.

- Preparing for a pre-IND meeting with the FDA.

- ARIUS intends to have clinical trials' materials prepared in the

fourth quarter of 2008 and then a Phase I IND application is expected

to be filed and human clinical trials commenced.

CD59 Complement Inhibitor Program

- Presented a CD59-focused poster at AACR Annual Meeting.

- Generated a cell line producing humanized CD59 antibody that

successfully retained binding characteristics and potent in vivo

activity.

- Preparing to perform preclinical toxicology studies planned for 2008

in preparation for a Pre-IND meeting with the FDA and filing a

Phase I IND application.

CD9 Cancer Stem Cell Program

- Presented a CD9-focused poster at AACR Annual Meeting.

- Presented positive findings demonstrating the ability of the lead

anti-CD9 antibody to kill cancer stem cells in an in vivo model using

cells from human leukemia patients at the American Association of

Cancer Research Special Conference on Cancer Stem Cells in the first

quarter of 2008.

CD63 Antibody Program

- Licensed to Genentech, Inc. in March 2006, the CD63 program continues

to advance in preclinical studies in a variety of cancer indications

as part of a program to move the lead antibody towards the clinic.

Takeda Collaboration

- Discovered and delivered novel antibodies to Takeda. Under the terms

of the research collaboration agreement, ARIUS has successfully met

its obligations to date and has received all scheduled research

payments from Takeda.

Additional Product Updates

- Current
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 A paper published today, " ... " in Science Translational Medicine, demonstrates ... reduce the risk associated with investing in the ... levels of funding for developing so-called "orphan" drugs. ... collaboration between scientists at the National Center for ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
(Date:2/26/2015)... , Feb. 26, 2015   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... Ph.D., President and Chief Executive Officer of Regulus, will ... 35 th Annual Healthcare Conference on Wednesday, March ... being held at the Boston Marriott Copley Place.  ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... 26, 2011 Sangamo BioSciences, Inc. (Nasdaq: SGMO ... quarter and full year 2010 financial results on Wednesday, February ... be followed by a conference call at 5:00 p.m. ET, ... webcast. During the conference call, the company will review the ...
... Calif., Jan. 26, 2011 Novel solutions to 21st ... Institute,s fourth annual executive education conference for female leaders ... 3-5, 2011. The Women Innovate Conference will ... and business ranging from small start-ups to global corporations. ...
... Ind. - Researchers are developing a new class ... advanced optical technologies, including ultrapowerful microscopes and computers, ... The new materials could make possible "nanophotonic" ... assistant professor of electrical and computer engineering at ...
Cached Biology Technology:Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast 2KGI Hosts Fourth Annual Conference for Women in Life Science Industry 2KGI Hosts Fourth Annual Conference for Women in Life Science Industry 3New materials may bring advanced optical technologies, cloaking 2
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
(Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
(Date:2/5/2015)... Calif. , Feb. 3, 2015 ... technology, demand from industries such as consumer electronics, ... market for surface mount technology (SMT) screen printers. ... to automatic control will push the adoption curve ... will remain steady as glue dispensers are indispensable ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... the first time points to a developmental mechanism linking ... and observed defects in brain wiring, according to a ... yesterday in Nature Neuroscience . These findings may ... disability and many other brain disorders. The present ...
... Shenzhen, China- An international research consortium, led by Fujian ... first genome sequence of the diamondback moth (DBM), the ... work provides wider insights into insect adaptation to host ... management. The latest study was published online today in ...
... microorganisms that live inside salt deposits in the acidic and ... extreme conditions of these microniches appear to be similar to ... Europa. This possibility should be borne in mind on missions ... doses of radiation, lack of moisture and extreme temperature and ...
Cached Biology News:New discovery in autism-related disorder reveals key mechanism in brain development and disease 2The genome of diamondback moth provides new clues for sustainable pest management 2The genome of diamondback moth provides new clues for sustainable pest management 3The saline hiding places for bacteria in Río Tinto could be like those on Mars 2
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
Request Info...
...
... is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Biology Products: